Helen I. Torley
2017
In 2017, Helen I. Torley earned a total compensation of $5.2M as President and Chief Executive Officer at Halozyme Therapeutics, a 7% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $699,115 |
---|---|
Option Awards | $1,900,003 |
Salary | $671,000 |
Stock Awards | $1,900,011 |
Other | $10,422 |
Total | $5,180,551 |
Torley received $1.9M in stock awards, accounting for 37% of the total pay in 2017.
Torley also received $699.1K in non-equity incentive plan, $1.9M in option awards, $671K in salary and $10.4K in other compensation.
Rankings
In 2017, Helen I. Torley's compensation ranked 1,795th out of 14,666 executives tracked by ExecPay. In other words, Torley earned more than 87.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,795 | 88th |
Manufacturing | 598 | 90th |
Chemicals And Allied Products | 158 | 92nd |
Drugs | 114 | 93rd |
Biological Products, Except Diagnostic Substances | 24 | 92nd |
Torley's colleagues
We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2017.
News
Halozyme Therapeutics CEO Helen Torley's 2021 pay rises 14% to $7.5M
March 25, 2022
Halozyme Therapeutics CEO Helen Torley's 2020 pay rises 11% to $6.5M
March 26, 2021
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019